Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time-Reference-Cited by-同舟云学术

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

Published:2017-11-16 Issue:4 Volume:32 Page:986-995
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kumar S K,Dispenzieri A,Fraser R,Mingwei F,Akpek G,Cornell R,Kharfan-Dabaja M,Freytes C,Hashmi S,Hildebrandt G,Holmberg L,Kyle R,Lazarus H,Lee C,Mikhael J,Nishihori T^ORCID,Tay J,Usmani S,Vesole D,Vij R,Wirk B,Krishnan A,Gasparetto C,Mark T,Nieto Y,Hari P,D'Souza A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017331.pdf

Reference33 articles.

1. Laubach J, Kumar S . Management of transplant-eligible patients with newly diagnosed multiple myeloma. Cancer Treat Res 2016; 169: 145–167.

2. Costa LJ, Zhang M-J, Zhong X, Dispenzieri A, Lonial S, Krishnan A et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1615–1624.

3. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017; 376: 1311–1320.

4. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.

5. Hari PN, McCarthy PL . Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant 2013; 19: S20–S25.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy;Frontiers in Bioscience-Landmark;2024-06-17

2. Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation;eJHaem;2024-06-16

3. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients;Cancer Immunology, Immunotherapy;2024-05-17

4. Time to progression predicts outcome of myeloma patients that can be influenced by autologous hematopoietic stem cell transplantation;2024-02-27

5. A rational approach to functional high-risk myeloma;Hematology;2023-12-08